uniQure NV Share Price Today: Live Updates & Key Insights

uniQure NV share price today is $16.37, up 5.44%. The stock opened at $15.27 against the previous close of $15.26, with an intraday high of $17.7 and low of $15.27.

uniQure NV Share Price Chart

uniQure NV

us-stock
To Invest in {{usstockname}}
us-stock

uniQure NV Share Price Performance

$16.37 0.0544(5.44%) QURE at 23 Mar 2026 02:57 PM Biotechnology
Lowest Today 15.27
Highest Today 17.7
Today’s Open 15.27
Prev. Close 15.26
52 Week High 71.50
52 Week Low 7.76
Day’s Range: Low 15.27 High 17.7
52-Week Range: Low 7.76 High 71.50
1 day return -
1 Week return +1.12
1 month return -34.25
3 month return -35.46
6 month return +16.64
1 year return +9.14
3 year return -13.75
5 year return -53.41
10 year return -

uniQure NV Institutional Holdings

FMR Inc 9.98

venBio Select Advisor LLC 9.84

RTW INVESTMENTS, LLC 5.94

Aberdeen Group PLC 5.88

State Street® SPDR® S&P® Biotech ETF 4.42

JPMorgan Chase & Co 3.68

Franklin Resources Inc 3.18

abrdn Healthcare Investors 2.59

Two Sigma Investments LLC 2.32

BlackRock Inc 2.31

State Street Corp 2.31

RTW Biotech Opportunities Ord 2.22

Jennison Associates LLC 2.19

Susquehanna International Group, LLP 1.95

Suvretta Capital Management, LLC 1.95

Two Sigma Advisers, LLC 1.78

Vanguard Group Inc 1.68

Artia Global Partners LP 1.64

Fidelity Advisor Biotechnology I 1.59

abrdn World Healthcare 1.58

Fidelity Select Pharmaceuticals Port 1.54

T. Rowe Price Associates, Inc. 1.46

Eversept Partners, LP 1.40

Millennium Management LLC 1.29

Geode Capital Management, LLC 1.24

Fiera Capital Corporation 1.23

abrdn Life Sciences Investors 1.19

Vanguard Institutional Extnd Mkt Idx Tr 1.08

Fidelity Select Health Care 1.07

Fidelity Select Biotechnology 1.04

JPMorgan Growth Advantage A 0.91

JPM US Mid Cap Growth-Composite 0.91

JPMorgan Mid Cap Growth I 0.91

Eventide Healthcare & Life Sciences I 0.80

abrdn Healthcare Opportunities 0.77

Franklin Biotechnology Discv A(acc)USD 0.76

JPM US Growth Advantage-MA 0.76

Fidelity Stock Selector Small Cap 0.74

HBM Healthcare Investments AG Ord 0.72

iShares Biotechnology ETF 0.68

uniQure NV Market Status

Strong Buy: 9

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

uniQure NV Fundamentals

Market Cap 1006.10 M

PB Ratio 5.0614

PE Ratio 0.0

Enterprise Value 447.58 M

Total Assets 824.91 M

Volume 5757928

uniQure NV Company Financials

Annual Revenue FY23:111899000 111.9M, FY22:106483000 106.5M, FY21:524002000 524.0M, FY20:37514000 37.5M, FY19:7281000 7.3M

Annual Profit FY23:105456000 105.5M, FY22:103140000 103.1M, FY21:499026000 499.0M, FY20:37514000 37.5M, FY19:7281000 7.3M

Annual Net worth FY23:-228465000 -228.5M, FY22:-126789000 -126.8M, FY21:329589000 329.6M, FY20:-125024000 -125.0M, FY19:-128011000 -128.0M

Quarterly Revenue Q3/2025:3701000 3.7M, Q2/2025:5262000 5.3M, Q1/2025:1567000 1.6M, Q3/2024:2287000 2.3M, Q2/2024:11126000 11.1M

Quarterly Profit Q3/2025:3303000 3.3M, Q2/2025:4606000 4.6M, Q1/2025:1370000 1.4M, Q3/2024:1266000 1.3M, Q2/2024:995000 1.0M

Quarterly Net worth Q3/2025:-80529000 -80.5M, Q2/2025:-37719000 -37.7M, Q1/2025:-43637000 -43.6M, Q3/2024:-44378000 -44.4M, Q2/2024:-56299000 -56.3M

About uniQure NV & investment objective

Company Information uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Organisation Biotechnology

Employees 221

Industry Biotechnology

CEO Mr. Matthew Craig Kapusta CPA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

uniQure NV FAQs

What is the share price of uniQure NV today?

The current share price of uniQure NV is $16.37.

Can I buy uniQure NV shares in India?

Yes, Indian investors can buy uniQure NV shares by opening an international trading and demat account with Motilal Oswal.

How to buy uniQure NV shares in India?

You can easily invest in uniQure NV shares from India by:

Can I buy fractional shares of uniQure NV?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of uniQure NV?

uniQure NV has a market cap of $1006.10 M.

In which sector does uniQure NV belong?

uniQure NV operates in the Biotechnology sector.

What documents are required to invest in uniQure NV stocks?

To invest, you typically need:

What is the PE and PB ratio of uniQure NV?

The PE ratio of uniQure NV is N/A and the PB ratio is 5.06.